Abstract 9824: Prevalence of Diagnostic Testing in Diagnosed and Undiagnosed Resistant Hypertension
Abstract
Background: Resistant hypertension, defined as hypertension refractory to three antihypertensive agents or hypertension which requires at least four agents to control, is associated with substantially increased cardiovascular risk. Current guidelines recommend evaluation for secondary hypertension in patients with resistant hypertension. However, adherence to these recommendations remains poorly characterized. Research Question: Are patients being appropriately evaluated for secondary causes of resistant hypertension? Methods: We performed a repeated cross-sectional analysis using data from the Epic Cosmos research network from January 1, 2016 through December 31, 2025. Adults with resistant hypertension were identified using 3 mutually exclusive cohorts: (A) diagnosis-based resistant hypertension; (B) use of 3 antihypertensive drug classes with continued hypertension; and (C) use of 4 antihypertensive drug classes. Annual rates of 6 guideline-recommended diagnostic evaluations: aldosterone testing, renin testing, renal imaging, sleep study, continuous positive airway pressure initiation, and cortisol testing. A composite “any test” outcome was also assessed. Trends were evaluated using Cochran-Armitage tests and multivariable logistic regression models adjusted for demographic and clinical covariables. Results: Among 7,853,400 patients with resistant hypertension, the proportion who received testing for secondary hypertension increased modestly across all cohorts from 2016 to 2025. In the diagnosis cohort, the proportion receiving any test rose from 16.7% to 23.7%, compared with smaller increases in the 3-drug-class cohort (7.9% to 10.7%) and 4-drug-class cohort (14.1% to 15.9%). Despite these gains, most patients had no evidence of evaluation in 2025 (76.3%, 89.3%, and 84.1% without testing in cohorts A, B, and C, respectively). Aldosterone and renin testing demonstrated the largest relative increases but remained infrequently performed (Fig. 1). Compared with the diagnosis cohort, patients in medication-defined cohorts had significantly lower adjusted odds of testing (aldosterone testing odds ratio, 0.15 [95% CI, 0.14-0.15] for 3-drug-class cohort). Persistent disparities were observed by social vulnerability, rurality, and geography (Figs. 2 and 3). Conclusions: In this large national study, evaluation for secondary hypertension diagnostic testing among patients with resistant hypertension increased over time but remained substantially underutilized, particularly among patients without a formal diagnosis. Further disparities between geographies point to regional barriers to adequate care. These findings highlight persistent gaps between guideline recommendations and clinical practice, underscoring the need for improved provider awareness, standardized implementation pathways, and equitable access to diagnostic testing.